Dyne Therapeutics/$DYN
1D1W1MYTD1Y5YMAX
Capital at risk
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
- Ticker
- $DYN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Waltham, United States
- Website
- www.dyne-tx.com
DYN Metrics
BasicAdvanced
$3.4B
-
-$3.35
1.08
-
Price and volume
Market cap
$3.4B
Beta
1.08
52-week high
$27.31
52-week low
$11.92
Average daily volume
2.5M
Financial strength
Current ratio
12.02
Quick ratio
11.515
Long term debt to equity
30.454
Total debt to equity
33.234
Interest coverage (TTM)
-36.05%
Profitability
EBITDA (TTM)
-534.805
Management effectiveness
Return on assets (TTM)
-38.96%
Return on equity (TTM)
-81.57%
Valuation
Price to book
4.35
Price to tangible book (TTM)
4.35
Price to free cash flow (TTM)
-5.723
Free cash flow yield (TTM)
-17.47%
Free cash flow per share (TTM)
-3.218
Growth
Earnings per share change (TTM)
-13.46%
3-year earnings per share growth (CAGR)
-0.79%
What the Analysts think about DYN
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
Analyst projections of the future price of Dyne Therapeutics stock.
Bulls say / Bears say
Z-rostudirsen has reached a major value-inflection point: the FDA accepted Dyne’s BLA for exon 51 DMD, granted Priority Review, and set a January 21, 2027 PDUFA target date, supporting a potential commercial launch in the first quarter of 2027. (Dyne Therapeutics)
Dyne is advancing a second potentially registrational asset: it completed enrollment of 71 participants in the ACHIEVE expansion cohort for z-basivarsen in DM1 and began dosing the global Phase 3 HARMONIA trial, with topline data planned for the first quarter of 2027. (Dyne Therapeutics)
The company has strengthened its development runway and pipeline optionality: cash, cash equivalents, and marketable securities totaled $898.5 million at June 30, 2026, the July financing extended expected funding into the second quarter of 2028, and FDA clearance of the DYNE-302 IND opened a clinical path in FSHD. (Dyne Therapeutics)
Regulatory approval is not assured: although the FDA accepted z-rostudirsen’s BLA and granted Priority Review, the application still faces a January 21, 2027 action date, while efficacy, safety, and confirmatory-trial requirements remain material risks. (SEC)
Dyne remains heavily loss-making and its cash burn is accelerating: second-quarter 2026 net loss was $178.6 million, while R&D and G&A expenses rose substantially year over year as the company funds clinical development and commercial preparations. (SEC)
The July 2026 equity offering of 21.045 million shares generated approximately $405 million in net proceeds but materially increased the share count, creating dilution risk for existing holders and signaling that additional capital may eventually be needed before products generate revenue. (Dyne Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
DYN Financial Performance
Revenues and expenses
DYN Earnings Performance
Company profitability
Upcoming events
No upcoming events
DYN News
AllArticlesVideos
Funds containing DYN
AllUSDGBPEUR
Fund name | Fund size | $DYN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.30% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.30% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.09% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.